Omnicell Inc. (OMCL) shares plummeted 10.56% in pre-market trading following the release of its fourth-quarter and full-year 2025 financial results.
The healthcare technology provider reported adjusted earnings per share of $0.40 for Q4 2025, missing the analyst consensus estimate of $0.50. While quarterly revenue of $314 million slightly exceeded expectations, the company posted a GAAP net loss of $2 million, reversing from a profit in the prior-year period.
Investors reacted negatively to the earnings miss and the company's outlook for fiscal year 2026, which includes adjusted EPS guidance of $1.65 to $1.85, below the consensus estimate of $1.88. The pre-market selloff reflects disappointment with both the quarterly performance and future earnings projections.